Fig. 8
From: Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation
Delayed tumor growth by inhibition of CTSS with recovery of BRCA1 expression. a Western blotting (total 8 tissues, upper) or immunohistochemistry (IHC) (total 4 tissues, bottom) for BRCA1 and CTSS was performed using rat mammary tumor tissues. b Western blotting was performed using MBA-MD-231 cells stably transfected of sh-CTSS, sh-BRCA1, and sh-CTSS/sh-BRCA1 (double deletion of CTSS/BRCA1) (upper). Changes in the tumor volume in xenografted SCID mice (n = 5/group) after injection of MDA-MB231 cells (1 × 107) were detected. Results are the means and standard deviations (*p < 0.05, Student’s t-test) (middle). Quantification of Ki67 positive cells after IHC analysis was performed (bottom) using image J software (NIH). *p < 0.05 (ANOVA). c Tumor growth measurement by treatment of oraparib in xenografted SCID mice (n = 5/group) at 28th day of MDA-MB-231 cells injection. *p < 0.05 vs. corresponding olaparib untreated control group and #p < 0.05 vs. olaparib untreated sh-control group (ANOVA). d IHC for BRCA1 and CTSS using human mammary cancer tissue microarray (n = 70), was performed using fluorescence-conjugated antibodies (CTSS: red; BRCA1: green). Photographs of four representative cancer tissues are presented. Quantification of BRCA1 positive and CTSS positive areas in each slide were analyzed using GraphPad Prism software 5.0
